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Abstract
A growing body of evidence indicates that natural killer (NK) cells are paramount to
the identification and elimination of cancerous and pre‐cancerous cells during
normal immunosurveillance. In addition, NK cells provide a vital link between the
innate and adaptive immune systems during an anti‐tumoral response. In the
present study, a novel fusion protein was designed from the extracellular portion of
mouse UL16‐binding protein‐like transcript 1 (MULT1), a ligand for the activating
NKG2D receptor on NK cells, and a short arginine‐glycine‐aspartic acid (RGD) ‐
containing peptide, which binds the integrin αvβ3 of tumor‐specific neovasculature.
In vitro studies showed that the fusion protein gene can be successfully
incorporated into the genome of B16 mouse melanoma cells, it can be transcribed
and translated efficiently, and it is appropriately secreted into the extracellular
milieu. In vitro studies also showed that the MULT1E‐RGD fusion protein
successfully binds the integrin αvβ3, and transfection with the gene does not affected
cell growth in B16 cells. In vivo studies indicate that transfected cancer cells, when
injected subcutaneously in C57BL mice, take on a new phenotype and a slightly
different growth pattern, consistent with an upregulated immune response to the
tumor.
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1.0 Introduction

1.1 OVERVIEW
Cancer is defined as the uncontrolled replication of formerly ‘normal’ cells, coupled
with the adoption of malignant behavior, including invasion and metastasis. This
definition, however, is undeniably simplified. Cancer relies upon infinitely complex
genetic and epigenetic changes in transformed cell populations, along with intricate
and highly variable interactions between the developing tumor and its environment.
In their seminal article, “The Hallmarks of Cancer,” Hanahan and Weinberg
attempted to organize the immeasurable complexities of cancer into a six major
categories of acquired capabilities (Fig. 1), which they deemed the six hallmarks of
cancer.
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Fig. 1: The 6 Hallmarks of Cancer. Cancer involves the acquisition of six major
capabilities, deemed the Hallmarks of Cancer by Hannahan & Weinberg, 2000

First, cancer cells develop the ability to replicate in the absence of mitogenic growth
signals. Some cancers accomplish this by producing their own growth factors, which
initiate replication by autocrine signaling loops. For example, glioblastomas have
been shown to produce their own platelet‐derived growth factor (Fedi, et al., 1997).
Yet another mechanism for self sufficiency in growth signals is the tendency of some
cancers to overexpress growth factor receptors, such as HER2/neu overexpression

2

MUL1E‐RGD Fusion Protein

Meg Steiner

in the case of breast cancer (Yarden & Ullrich, 1988). This allows receptors to
become overly responsive, sometimes reacting even to ambient levels of extrinsic
growth factor (Fedi, et al., 1997). Finally, many cancers avoid the need for extrinsic
growth signals by altering their intracellular signaling pathways. It has been
estimated that about 25% of human tumors have mutated Ras proteins, which are
involved in the extremely complicated SOS‐Ras‐Raf‐ cascade. When present in
structurally altered forms, Ras proteins enable the release of a flux of mitogenic
signals regardless of extracellular factors (Giancotti & Rouslahti, 1999).

Like in the case of growth signals, normal tissues also rely on the presence of
extrinsic anti‐growth signals to remain in equilibrium with their surroundings.
Cancer cells, on the other hand, develop an insensitivity to these anti‐growth signals.
One way many cancers accomplish this is to downregulate expression of receptors
for growth‐inhibiting factors, such as TGF‐β (Moses, et al., 1990). Additionally,
cancer cells may alter the particular cell adhesion molecules they express so as to
replicate regardless of tethering to extracellular matrix or to other cells. Specifically,
tumor cells often alter their expression of integrins so as to transduce mitogenic
signals rather than growth‐inhibiting signals (Desgrosellier & Cheresh, 2010).

Following the acquisition of self‐sufficiency in growth signals and insensitivity to
anti‐growth signals, cancer cells develop mechanisms for evading apoptosis. Some
cancers do this by upregulating anti‐apoptotic genes such as PI3‐kinase and Akt
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(Evan & Littlewood, 1998). Others lose expression of tumor suppressor genes such
as PTEN (Downward, 1998). Both of these mechanisms for evasion of apoptosis
interfere in intracellular processes. Other mechanisms may evolve to evade
extracellular pro‐apoptotic signaling. Many ways of abrogating the FAS‐mediated
cell death pathway have been identified in tumors (Pitti, et al., 1998).

Next in the path toward carcinogenesis, cancer cells adopt limitless replicative
potential. Even with the previous three acquired capabilities, normal cell will only
replicate a given number of times before they enter a ‘crisis state’ and ultimately
undergo cell death due to karyotypic disarray. The means by which cancer cells
acquire their hallmark immortal character has to do with their ability to prevent the
degradation of their chromosomes during replication. All cells have telomeres on
the end of their chromosomes, which are gradually degraded with every cell
division. When telomeres become completely degraded over a period of time due to
replication, the chromosome becomes compromised. The cell can no longer divide
and undergoes apoptosis. Cancer cells, however, are able to activate an enzyme
called telomerase, which effectively prevents this cap to replication by adding
trinucleotide repeats to the end of chromosomes during every mitotic division (Shay
& Barcchetti, 1997).

The final steps toward carcinogenesis are sustained angiogenesis and tissue
invasion and metastasis. Tumors require sustained angiogenesis in order to grow to
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a diameter of any more than about 2cm. The ability to recruit and harbor a complex
circuit of tumor‐associated vasculature, therefore, is vital for tumor growth and for
eventual metastasis. Tumors may accomplish this task by a number of different
mechanisms, including the upregulation of soluble growth factors such as vascular
endothelial growth factor (VEGF) and fibroblasts growth factors 1 and 2 (FGF1/2).
Tumors may also downregulate inhibitors such as thrombospondin and B‐
interferon. Tissue invasion and metastasis occurs by some of the same mechanisms
as angiogenesis. In addition, tumors lose adhesion molecules, such as N‐CAM and E‐
cadherin, that bind them to their surrounding environment and ECM. Tumors also
change integrin expression from those that prefer normal epithelial basement
membrane to those that prefer degraded stromal components, which in turn guide
them toward blood vessels and eventually into the blood stream (Desgrosellier &
Cheresh, 2010).

In addition to Hanahan and Weinberg’s proposed paradigm for cancer, it was
proposed in 2009 that a seventh Hallmark of Cancer be added to Hanahan and
Weinberg’s paradigm: inflammation. A growing body of research indicates that
inflammation plays a pivotal role in the progression of cancer. These claims have
been made for several different reasons. First, inflammation provides a unique
setting for cancer because of the tissue damage that is often associated with it.
Inflammation is marked by proteases, which degrade the stroma around the
developing tumor. In addition, reactive oxygen and nitrogen species released by
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macrophages during inflammation not only contribute to tissue damage, but also
provide a mechanism for the development of further genetic instability, associated
with cancer. Next, inflammation provides a wealth of growth signals as well as
angiogenesis mediators, which the developing tumor readily utilizes. Finally, the
inflammation around a tumor works to recruit an immune response to that tumor.
Although immune system involvement in a tumor may sound like a positive effect of
inflammation, some propose that the presence of immune cells in a developing
tumor may in fact promote its progression (Colotta, et al., 2009). Specifically, it has
been argued that the inflammatory microenvironment surrounding a growing
tumor places selective pressures on the tumor, allowing certain cells to develop
preferentially, based on their ability to evade the immune system. This concept is
often referred to as ‘immunoediting’ (Fig. 2).

Fig. 2: Immunoediting. Normal cells undergo oncogenic transformation, then immune system
places selective pressure to produce immune‐evasive subpopulation. (Raulet & Guerra, 2009)
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Currently, the link between cancer and inflammation is a subject of hot debate.
Although the role of inflammation in tumor progression and metastasis is
increasingly accepted, controversy surrounds the idea of exactly how the immune
system, as a whole, may contribute to cancer versus how the immune system may
combat it.

Traditionally, cancer has been treated by one or both of two major classes of
therapy: chemotherapy and radiation therapy. These two types of cancer treatment
aim to stymie the proliferative nature of cancer by directly killing the cells that
compose it. Radiation is a more localized approach to cancer treatment, wherein
radioactive fields are applied to the malignant tumor and a small margin of the
surrounding tissue, often including the draining lymph nodes (Camphausen &
Lawrence, 2008). Chemotherapy, on the other hand, is a more systemic approach to
cancer treatment. Since one of the main characteristics of cancer is its ability to
disseminate microscopic portions of the primary tumor, which can subsequently
invade distant regions of the body, it is often necessary for patients to undergo this
kind of universal treatment. The word chemotherapy refers to a wide range of
cytotoxic drugs and drug combinations that work by exterminating rapidly dividing
cells. Although chemotherapy is often effective against malignancies, the side effects
of any therapy with such potent cytotoxic characteristics are often devastating.
Specifically, since chemotherapy aims to eradicate growing cell populations, it often
attacks non‐transformed cell and tissue types that naturally grow constantly, such
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as hair follicles, nail beds, bone marrow, and gut epithelium. This non‐specific
nature of chemotherapy explains the common side effects of chemotherapy:
alopecia (hair loss), mucositis (degradation and inflammation of the gut lining), and
myelosuppression (decreased population of blood cells) (Hirsch, 2006).

Of particular interest, the myelosuppressive effects of chemotherapy may have more
injurious consequences than was originally suspected. Depletion of the blood cell
population implies a depletion of the immune system. Accordingly, cancer patients
are significantly more susceptible to infection – a fact that has been well recognized
since the beginning of chemotherapy. However, recent research indicates a
significant role of the immune system in preventing and combating cancer (Chabner
& Longo, 2006).

1.2 IMMUNOTHERAPY
In light of growing evidence supporting the effectiveness of the immune system in
fighting cancer, much of the medical community has begun to explore new avenues
for cancer treatment. Many strategies work to employ the immune system, rather
than attack it. These treatments often fall under the heading of immunotherapy.
Immunotherapy is defined as “treatment of disease by inducing, enhancing, or
suppressing an immune response” (American Heritage Medical Dictionary. 2007).
Within the context of cancer treatment, it has been proposed that strategies such as
Coley’s toxin may stimulate the immune system in a broad sense, thereby eliciting
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an anti‐cancer response by indirect means (MD Anderson, 2006). Although Coley’s
results may have provided the foundation for immunotherapy for cancer, current
research focuses on much more specific, targeted therapies. With increasing
exploration of the immune system’s role in fighting cancer, as well as the
progressive characterization of the cancer cell phenotype, the potential for driving a
specific, anti‐cancer immune response is becoming more and more plausible.

Current immunotherapy research relies heavily on the concept of immune
surveillance. Immune surveillance is the term used to describe the body’s natural
ability to scan and eliminate “abnormal cells.” These cells may be invaders such as
bacteria, and will therefore be recognized by immune cells and elminated due to
their non‐self nature. In the context of cancer, however, the immune system must
recognize cells that are self, but have been altered. The major player in tumor
surveillance is the natural killer cell (NK cell) (Smyth, et al., 2001).

1.3 NATURAL KILLER CELLS
1.3.1 Natural killer cells in innate immunity
Natural killer cells are a class of lymphoid cells that respond to viruses and
intracellular pathogens. They make up around 15% of the peripheral blood
lymphocytes and are also resident in peripheral tissues such as the liver, peritoneal
cavity and the placenta. Although they develop from the common lympoid
progenitor cell, NK cells can be distinguished from B and T cells under the

9

MUL1E‐RGD Fusion Protein

Meg Steiner

microscope by their larger size and distinctive cytoplasmic granules. Functionally,
NK cells are markedly different from their other lymphoid relatives as well. Namely,
NK cells can be activated without prior immunization or stimulation, indicating their
role in the innate rather than the adaptive immune system. Rather than the later
onset cytokines such as interferon gamma (IFN‐γ), NK cells are stimulated by
cytokines such as IFN‐α, IFN‐β, TNF‐α, and IL‐12. Adding to the evidence that NK
cells are in fact part of the innate immune system is their lack of variant receptors.
Although the mechanism that NK cells employ to attack their target cells is similar to
that employed by cytotoxic T cells, it is triggered by invariant receptors that
recognize hallmarks of virally infected or transformed target cells, unlike the highly
specific interaction that takes between the T cell receptor and its particular target
cell. This makes NK cells more effective against infected and transformed cells in the
early stages of infection (Murphy, et al., 2008).

In addition to their established role in eliminating viruses, NK cells appear to be a
first line of defense against tumor formation. Several studies have found that
depletion of NK cells in vivo makes mice significantly more susceptible to tumor
formation (Smyth, et al., 2001). Over the last decade, wealth of research has
emerged focusing on the role of NK cells in tumor immunity.

1.3.2 Natural killer cells in cancer recognition
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NK cells are typically able to recognize and attack tumor cells on the basis of two
features: tumor cells often lack specific ‘self’ molecules, such as class‐I MHC
proteins, which prevent NK cell activation through specific inhibiting receptors on
the NK cell surface (Long E, 1999). In addition, tumor cells sometimes upregulate
certain molecules that indicate cell stress, transformation or infection. These
molecules interact with specific activating receptors on the natural killer cell
membrane, and initiate a stimulatory intracellular response (Viver, et al., 2008). NK
cells are activated or inhibited based on a collective balance of activating and
inhibiting signals. For an NK cell to become active, typically the inhibitory signal –
which includes ‘self’ or healthy cell markers like MHC class I molecules – must be
removed (Colotta et al. 2009). Many tumor cells shed or downregulate MHC class I
proteins in an effort to prevent cytotoxic T cell response. Without MHC class I
molecules expressed on the surface of the cancer cell, however, NK cells are released
from the inhibitory signal transduced by Ly49 (in mice), KIR (humans), and the
CD49/NKG2A receptor (Raulet & Nadia, 2009). Thus, NK activation status hinges
upon a delicate balance between activating and inhibiting signals transduced from
the various receptors on the NK cell surface (Fig. 3)
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Fig. 3: NK cell activation status depends on balance of stimulatory and inhibitory signals.
When signals are balanced, cell remains inactive. When activating signals outweigh inhibiting
signals, cell becomes active. (Diefenbach & Raulet, 2002)

The second feature of the NK cell that allows it to be so active against cancer has
only recently been explained. In addition to the delicate balance that works to
maintain NK cells in an active or passive state, there exists a potent activating
receptor on the surface of NK cells: the NKG2D receptor. NKG2D may also be
expressed by other cell types such as activated cytotoxic CD8+ T lymphocytes and
NKT cells. NKG2D recognizes various markers that are upregulated on tumor cells
and virally infected cells, but not well represented on uninfected cells (Raulet &
Nadia, 2009). Among these ligands is the protein MULT1 (in the mouse), which this
particular study has utilized. Upon recognition of its ligands, NKG2D drives a potent
cytotoxic response, immediately rejecting cells of transformed nature. (Fig. 4)
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Fig. 4: Ligands for the NKG2D
activating receptor are expressed
on cells in response to infection,
transformation, or stress. Binding
of NKG2D to its ligands causes
signaling cascade that results in
NK cell activation: release of
perforin and granzyme, secretion
of cytokines IFN‐γ, TNF‐α, and
GM‐CSF.
Cerwenka & Lanier, 2001

Although many other populations of cells are important for immune surveillance,
the necessity of the NK cell population was made obvious when NK cell deficient
mice received transplanted tumors. In comparison with immunologically normal
mice, NK cell deficient‐mice were significantly more susceptible to the tumors
(Cerwenka & Lanier, 2001; Ljunggren & Karre, 1985; Seaman, et al., 1987).
Interestingly, mice deficient in T and B lymphocytes did not show similar
susceptibility, indicating that NK cells are in fact the major players in immune
surveillance against cancer.
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A demonstration of the importance of NK cells, and specifically of the NKG2D
receptor, was established when NKG2D‐deficient mice were studied (Guerra, et al.,
2008). In the TRAMP mouse model, a specific form of highly aggressive prostate
adenocarcinoma was found to spontaneously arise at an alarming frequency. In
comparing the adenocarinomas in NKG2D‐deficient mice to the adenocarcinomas of
mice with normal NKG2D expression, it was foudthat deficient mice developed
tumors that expressed one or more NKG2D ligands, whereas tumors in NKG2D‐
sufficient mice commonly expressed no NKG2D ligands. It was porposed that those
adenocarcinomas that developed in NKG2D‐sufficient mice were targeted by
NKG2D‐mediated immune surveillance. This resulted in the selection of variant
tumor cells that lost expression of NKG2D ligands (Fig. 5) (Raulet & Guerra, 2009).
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Fig. 5: mouse model for immunoediting via NKG2D. a) The highly malignant tumors in the
NKG2D‐deficient TRAMP mice generally express NKG2D ligands, whereas the rarer tumors of
this type in NKG2D‐sufficient mice generally lack NKG2D ligands, suggesting that the immune
response modifies these tumors by selecting for variant tumor cell lines that fail to express
NKG2D ligands. b) by contrast, the less aggressive, late developing tumors express NKG2D
ligands regardless of whether NKG2D is expressed, suggesting that these tumors evade
NKG2D‐depenent elimination by a distinct mechanism. (Raulet & Guerra, 2009).

1.3.3 Natural killer cell activation

15
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In this study, the extracellular portion of a mouse NKG2D ligand, mouse UL16‐
binding like protein 1 (MULT1), was fused with a short peptide sequence, arginine‐
glutamine‐aspartic acid (RGD), which binds integrin αvβ3. The purpose of the
MULT1E portion of the MULT1E‐RGD fusion protein is to direct an NK cell‐mediated
immune response, which will be localized to the tumor microenvironment by way of
RGD interaction with the surrounding tumor vasculature.

MULT1E interaction with the NKG2D
receptor inspires a signal cascade
beginning on the cytosolic domain of
the NK cell receptor. NKG2D interacts
with the adaptor protein DAP10.
Subsequent recruitment and activation
of phosphatidyl inositol‐3 kinase results
in the activation of ERK and Akt, which
ultimately result in the production of
cytokines, increased NK cell survival,
and the initiation of cytotoxicty
(Cerwenka & Lanier, 2001).

Cell killing by NK cells requires direct cell

Fig. 6: The perforin‐granzyme cell killing
mechanism. Trapani & Smyth, 2002
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contact between effector and target. Killing may occur by two pathways: in the first, a
membrane puncturing protein called perforin and a group of serine proteases called
granzymes are secreted by exocytosis into the fluid surrounding the target cell. As
perforin pierces the membrane, granzyme enters and begins to digest the intracellular
contents. Between the disruption of the membrane and the toxic environment within, the
cell is under a great deal of stress. In addition, granzyme may actually directly activate
cell death pathways through interaction with apoptotic caspases. Thus, the perforin
granzyme pathway induces rapid apoptosis of target cells (Fig. 6). The second cell death
pathway occurs when FAS ligand on the killer-cell membrane causes target cell death
receptors, such as FAS (CD59) to aggregate on target cell membrane. The result is the
initation of classical caspase-dependent apoptosis (Trapani & Smyth, 2002).

1.3.4 Natural killer cells link innate and adaptive immunity
In addition to direct attack of target cells, activated NK cells also secrete the
pleiotropic cytokine interferon gamma (IFN‐γ), which is indispensable for the
activation of antigen‐presenting cells (Walzer, et al., 2005) and also for the
installment of TH1 responses (Martin‐Fontecha, et al., 2004). In addition to
lymphocyte recruitment and activation, IFN‐γ has been implicated in angiogenesis
inhibition (Qin & Blankenstein, 2000). Thus, activation of NK cells in the tumor
microenvironment would not only elicit an NK‐cell mediated immune response
against the tumor and its associated vasculature, but it would recruit an adaptive
immune response as well (Wendel et al., 2008) (Fig. 7).
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Fig. 7 – NK cells link innate & adaptive immunity: Secreted IFN‐γ from activated natural killer
cells interacts with lymphocytes to direct tumor infiltration. Simultaneously, lymphocytes secrete
chemokine CXCL10 which direct highly active CD27high NK cells to the site of the tumor.

1.3.5 Natural killer cells and patient prognosis
In line with the hypotheses that a strong immune response to tumors would
improve the overall outcome of the patient’s disease, and that a strong anti‐tumor
response is initiated by NK cell involvement in the tumor microenvironment,
significant research supports that NK cell infiltration in tumors is directly correlated
with patient survival. A 1997 study found that colorectal carcinoma patients with
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little to moderate NK cell tumor‐infiltration had significantly shorter survival rates
than those with extensive infiltration (Coca, et al., 1997). A subsequent study in
2000 found similar results in patients with gastric carcinoma. In this study, patients
with high NK cell infiltration not only had longer survival, but they had fewer
metastases and less lymph node involvement (Ishigami, et al., 2000). In 2001 and
2002, two studies found similar results with lung cancer (Takanami, et al., 2001;
Villegas, et al., 2002). These clinical results indicate that NK cell activation is
paramount to a strong anti‐tumor immune response, and that such an immune
response is paramount to overall disease progression and patient survival.

1.4 INTEGRIN αvβ3

1.4.1 Angiogenesis and cancer
The RGD portion of the MULT1E‐RGD fusion protein is designed to target the tumor‐
associated vasculature. A requirement for the development of tumors – both solid
and hematologic (Padro, et al., 2007) – is the recruitment and growth of new
vasculature. In addition to supplying tumors with nutrients, blood vessels also
supply tumors with a receptacle for waste products which would otherwise build up
on the core of the mass and cause necrotic cell death (Risau, 1997). Importantly,
angiogenesis is also vital for the progression of primary cancer to a metastatic state
(Zetter, 1998). Thus, it is postulated that blocking angiogenesis would not only
starve tumors individually, but it could stop their spread as well (Bergers, et al.,
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1999). Angiogenesis involves complex molecular processes of cell recruitment,
differentiation and secretion and teathering to the extracellular matrix surrounding
forming blood vessels (Risau, 1997). Because this process is so specific, it provides
researchers with several tumor angiogenesis‐associated markers, including VEGF,
integrin αvβ3 and integrin αvβ3.

The potential exploitation of the tumor‐specific angiogenic process has become a
hot topic for cancer research over the last 10 years. Many studies have focused on
inhibiting the growth of new blood vessels by employing antiangiogenic agents such
as angiostatin and endostatin (O’rielly , et al., 1997; Bergers, et al., 1999). These
processes, however, require that the therapy directly interfere with the intricate
processes of angiogenesis. In this study angiogenesis is indirectly inhibited by
targeting an immune‐inspring agent, MULT1, to markers on the tumor‐associated
vasculature. The RGD portion of MULT1E‐RGD targets with high affinity a family of
integrins, deemed αvβ3, which have been found to be tumor specific (Brooks, et al.,
1994).

1.4.2 Integrin αvβ3 in tumorassociated angiogenesis
The word integrin refers to a diverse family of cell adhesion receptors which
mediate a myriad of cellular functions. Research has shown that integrins are vital
to the initiation, progression and metastasis of solid tumors (Desgrosellier &
Cheresh, 2010). Integrins have been implicated in tumor cell proliferation,
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migration and survival. Their role in cell migration relies on their ability to directly
bind the components of the extracellular matrix (ECM). They act by way of a
ratcheting mechanism that allows tumor cells to “crawl” along, effectively invading
the ECM and tumor microenvironment, often leading to blood vessel intrusion and
subsequent metastasis (Guo & Giacotti, 2004). Integrins also mediate invasion of the
microenvironment through their ability to aid in the remodeling of the ECM. They
do this by regulating the localization and activity of proteases (Guo & Giancotti,
2004). Integrins have also been shown to regulate tumor cell proliferation, even in
the absence of adhesion‐dependent replication control mechanisms (Vellon, et al.,
2005, Assoian & Klein, 2008) (Fig. 8). Finally, almost all of the currently identified
integrins are expressed by endothelial cells, especially during angiogensis (Brooks,
Clark & Cheresh, 1994). Because of the profound role of integrins in tumor
initiation, progression, and ultimate metastasis, they have been proposed as
potential targets for therapy as well as diagnosis of the malignant potential of a
given tumor. However, the integrin

family

is

very

broad, and the majority of
integrins are expressed in
many normal tissues, if not
ubiquitously (Desgrosellier &
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Cheresh, 2010).

Fig. 8: Integrin expressed on
or near tumor cells can aid in
survival, migration and
invasion, and proliferation.
Desgrosellier & Cheresh, 2010

The integrin αvβ3, which this study targets with the RGD portion of the fusion
protein, has been specifically implicated in several different cancers (Fig. 9). The
αvβ3 integrin is essential for tumor associated angiogenesis, lymphangiogenesis, and
desmoplasia. In addition, αvβ3 is expressed at low or undetectable levels in normal,
non‐tumor‐associated tissues (Brooks, Clark & Cheresh, 1994). Therefore, this
particular integrin presents a promising means of targeting tumor neovasculature.
Of particular interest, however, is

the

Fig. 9: Integrin αvβ3 is expressed on several different cancer cell lines, and is one of the few
integrins that is highly specific to cancers. Desgrosellier & Cheresh, 2010
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identification of antagonists to the αvβ3 integrin versus agonists. It appears that the
ability to activate the receptor, as opposed to inhibit it, may rely many
characteristics of the ligand. For example, some research has found that certain
extracellular matrix proteins such as vitronectin and fibronectin may activate
integrin αvβ3 signaling, however similar proteins in soluble form may, in fact, inhibit
it (Berrier & Yamada, 2007). Interestingly, integrin αvβ3 cross‐talk in tumor‐
associated endothelial cells with angiogenesis‐associated receptors, fibroblast
growth factor receptor (FGFR) and vascular endothelial growth factor receptor 2
(VEGFR2), has been found to prevent intrinsic and extrinsic apoptosis, respectively
(Hood, et al., 2003; Alavi, et al., 2003). This indicates that integrin αvβ3 , and
perhaps other integrins, may act synergistically with various oncogenes to further
promote tumor progression. Given the specificity of integrin αvβ3 to the tumor‐
associated vasculature, and the potent effects observed when the integrin is
activated and inhibited (Fig. 10), much research has focused on exploiting it for its
potential therapeutic value.
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Fig. 10: Integrins expressed on many cancer‐related cell types. Step 1: integrins in
endothelial cells regulate migration, proliferation and survival necessary for
angiogenesis. Step 2: integrins mediate the binding of endothelial cells to pericytes,
which aids in subsequent pericyte recruitment. Step 3: cytokines and growth factors from
myeloid cells and monocytes help initiate angiogenesis and tumor cell migration. Step 4:
integrins aid in directing myeloid cells and monocytes to tumors, as well as desmoplasia.
Step 5: invading fibroblasts deposit collagen that may make tumor resistant to treatment.
Step 6: integrins regulate growth factor secretion by tumor associated fibroblasts.
Integrins may also control platelet expression, which may ultimately aid in metastatic
dissemination. Desgrosellier & Cheresh, 2010
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1.4.3 Exploitation of Integrin αvβ3  RGD
RGD was first identified as a major player in cell adhesion in 1985 (Pytela, et al.,
1985), and its interaction with integrin αvβ3 was characterized by 1988 (Smyth &
Cheresh, 1988). By 1994, use of RGD as an αvβ3 antagonist was confirmed to
directly inhibit angiogenesis in a tumor model (Brooks, et al., 1994). Over the last 10
years, RGD has become a well‐recognized tool for targeting anti‐tumoral and anti‐
angiogenic agents to tumors and tumor‐associated vasculature by way of its
interaction with integrin αvβ3. RGD has been utilized as an integrin antagonist in
several studies ranging from in vitro experiments all the way to pre‐clinical and
clinical studies. Consistently, it demonstrates potent inhibition of tumor
progression. Currently, Phase III clinical trials on an RGD‐containing drug called
Cilengitide are under way, and showing promising results and few side effects
(Reardon et al., 2008).

1.5 THIS STUDY
Given the proven success of RGD in targeting tumors, and the well‐established
ability of MULT1 to activate natural killer cells by way of their NKG2D receptors, the
following study tested the effects of transfecting mouse B16 melanoma cells with
the gene for a fusion protein, MULT1E‐RGD, on in vitro and in vivo tumor growth. In
addition, the study tested the efficacy of the MULT1E‐RGD fusion protein in binding
immobilized integrin αvβ3. The portion of the MULT1 gene encoding the
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extracellular domain of the protein was reverse‐transcribed from mouse
thymocytes, then linked to the gene for the hinge domain of mouse IgG. The gene
encoding the RGD peptide (ACDCRGDCF) was included in a reverse primer, to be
employed in a polymerase chain reaction. PCR successfully amplified the MULT1E‐
RGD gene, which was inserted into a vector that inserted a signal sequence on the
end of the RGD peptide, such that the ultimate protein would be secreted by the cell.
In accordance with predictions, MULT1E‐RGD was secreted effectively bound
integrin αvβ3 in vitro. Relative to B16 cell lines not expressing the fusion protein,
MULT1E‐RGD‐expressing B16’s did not grow at a significantly different rate in vitro,
however a significant difference in tumor growth and progression was observed in
vivo.
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2.0 Materials and Methods

2.1 CONSTRUCTION OF RECOMBINANT MULT1E‐RGD VECTOR:
The extracellular domain of the murine ULBP‐like transcript 1, MULT1E, was fused
with a short peptide sequence incorporating the arginine‐glutamine‐aspartic acid
(RGD) motif. RGD was embedded within the peptide sequence ACDCRGDCF (Li J, et
al., 2004). The MULT1E‐RGD gene construct was then inserted into a recombinant
expression vector.

Briefly, the MULT1E‐RGD gene construct was created by a series of steps. First,
mRNA encoding the extracellular portion of MULT1 was reverse transcribed from
mouse thymocytes. A hinge domain taken from a gene for mouse IgG was then
added to the cDNA by way of PCR (Kotturi, et al., 2008). Finally, PCR was run using
the MULT1E + hinge DNA construct as the DNA template. Primers were designed
such that the final gene construct would include restriction enzyme recognition sites
at either end of the gene. In addition, the reverse primer included the sequence
encoding the RGD peptide, along with a piece of the hinge portion of the template
DNA. Primers used looked like:

MULT1E‐5’ HindIII Forward primer:
5’ CCCAAGCTT ATG GAG CTG ACT GCC AGT AAC AAG GTG C 3’
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RGD‐hinge‐3’ BamHI Reverse primer:
5’ CG GGA TCC TCA GCC GCA GAA ACA ATC TCC TCG GCA GTC GCA GGC TC CGG CCT
GTA CAT ATG CAA GGC 3’

The final gene construct (Fig. 11 A & B) would include, in the 5’ to 3’ direction, a
restriction enzyme recognition site for HindIII, the MULT1E gene, the gene for the
hinge domain of the protein, the RGD‐encoding sequence, and finally a restriction
enzyme recognition site for BamHI.

PCR product was purified by gel electrophoresis on a 1% agarose gel and
subsequent gel extraction (Qiagen). Next, the gene construct was inserted into the
recombinant vector, pcDNA3.1 (+) (Invitrogen) (Fig. 11C). Briefly, both the vector
and the PCR product were digested with the restriction enzymes BamHI and HindIII.
Following gel purification (Qiagen), a ligation reaction (Epicentre Fast‐Link™) was
run so as to insert the gene construct into the recombinant vector (Figure 11D),
which included a signal sequence at the end of the MULT1 portion of the protein.
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A
3 bp

STOP
73 bp

Hinge

RGD
MULT1E
33 bp
633 bp

HindIII

BamHI

9 bp

6 bp

B.
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C.

D.

CMV

MULT1Extracellular

RGD

Figure 11: Construction of the MULT1E‐RGD‐containing plasmid. A: putative gene
construct containing extracellular portion of MULT1 (MULT1E), IgG hinge region, and
RGD peptide, plus restriction enzyme digest regions for BamHI and HindIII. B: gene
sequence for MULT1E‐RGD, following PCR to fuse RGD to MULT1E‐hinge. C: pcDNA3.1
recombinant expression vector, into which MULT1E‐RGD is inserted, containing sites for
restriction enzyme digest and antibiotic resistance. D: resultant plasmid containing
MULT1E‐RGD fusion protein gene
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2.2 TRANSFORMATION OF COMPETENT CELLS WITH pMULT1E‐RGD:
Invitrogen Max Efficacy DH5α™ chemically competent cells were thawed and
incubated on ice for 30 minutes in the presence of 2ul of ligation reaction product.
Cells were then transformed by heat shock and subsequently shaken for one hour in
S.O.C. media at 37oC, 225 g‐force. Finally, cells were spread on ampicillan‐containing
LB plates and incubated overnight at 37oC. Colonies were isolated from the plates
after 24 hours, cultured in a selective ampicillan‐containing LB broth overnight, and
finally harvested for DNA extraction (Quiagen). After DNA extraction by miniprep
(Zymo Research™ Miniprep protocol), plasmid DNA was digested with BamHI and
HindIII restriction enzymes and run on a .7% gel to identify colonies which
appeared to have replicated plasmid DNA of the appropriate size. Six colonies were
chosen for sequencing, and resultant sequences were compared to the fusion
protein DNA construct.

Two pMULT1E‐RGD‐positive colonies (as confirmed by sequencing) were chosen
for further amplification of the plasmid DNA. Colonies 1a and 13c were cultured and
plasmid DNA was extracted according to the Qiagen Midiprep protocol. Quantity of
plasmid DNA was then determined by UV absorbance specrometry and appropriate
gene sequence length was re‐confirmed by restriction enzyme digest with BamHI
and HindIII.
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2.3 TRANSFECTION OF B16 MOUSE MELANOMA CELLS WITH pMULT1E‐RGD:
The mouse B16‐F0 cell line was used for transfection studies. Briefly, pMULT1E‐
RGD isolated from midiprep 1a was linearized using the restriction enzyme BstB1.
B16 cells were cultured on a 6‐well plate for 48 hours prior to transfection with
linearized pMULT1E‐RGD conjugated with Lipofectamine 2000™ transfection
reagent (GIBCO). Transfection was performed on 2 wells of ~85% confluent B16
cells. One well would ultimately be used for selection of stable clones, whereas the
other would be analyzed for mRNA analysis forty‐eight hours after transfection.

2.3.1 Transient Transfection:
Forty‐eight hours after transfection, one of the two wells of the 6‐well‐plate treated
with trypsin to harvest B16’s, and RT‐PCR was performed to analyze expression of
MULT1E‐RGD fusion protein gene (MasterAmp™ High‐Fidelity RT‐PCR Kit,
Epicentre). PCR product was run on a 1.5% gel for visualization of RNA expression.

2.3.2 Establishment of Stable Cell Lines:
Transfected B16 cells were cultured in selective medium containing G418 sulfate
(Geneticin®, by Invitrogen) at a concentration of 1mg/mL. When cultured at a very
low initial concentration, it was possible to observe the formation of specific and
visible clones after about 1.5 weeks in culture. Clones were then transferred
individually to separate wells, by way of cloning papers, for subsequent expression
analysis. Following the establishment of stable cell lines, mRNA expression of the
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MULT1E‐RGD gene was analyzed by way of RT‐PCR (MasterAmp ™ High‐Fidelity
RT‐PCR Kit, Epicentre). PCR products for each clone were run on a 1.5% gel (Fig.
17B) to visualize presence or absence of MULT1E‐RGD gene, as well as presence of
β‐actin gene in all cell lines.

2.4 MULT1E‐RGD PROTEIN CONFIRMATION:
By way of a specially designed enzyme‐linked immunosorbent assay (ELISA)
protocol (Stilletti, et al., 2001), translation of the MULT1E‐RGD gene to protein was
confirmed. Forty eight hours before protein analysis, cells were seeded on 6 well
plates in either regular medium containing 10% FBS, or in minimal‐serum medium.
Briefly, microtiter wells were coated with integrin αvβ3 (Millipore ™). Fifty uL of
integrin αvβ3, at a concentration of 2.5 ug/mL, were added to wells of a 96‐well
plate. Plates were incubated at 37oC in 5% CO2 overnight. Prior to incubation with
medium, wells were blocked with 1% BSA. 100ul medium from established cell
lines either positive for MULT1E‐RGD transcription or negative for MULT1E‐RGD
transcription (Fig. 17B) was added to appropriate wells and incubated overnight at
37oC. Following thorough washes of wells, primary antibody against the MULT1
portion of the protein, rat anti‐mouse MULT1 antibody, was added to wells and
incubated at room temperature for 30 minutes. Finally, a secondary antibody: goat
anti‐rat IgG conjugated to a fluorescent reporter, fluorescein isothiocyanate (FITC),
was applied to the wells and incubated for 30 minutes. Following thorough washes,
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the plate was read for fluorescence on a Gemini XS™ fluorescence microplate reader
(Molecular Devices). High fluorescence values indicated presence of secreted fusion
protein in medium. Each cell line was tested for protein translation in regular and
minimal‐serum medium, and each treatment group was tested in triplicate. Figure
12 gives a schematic representation of the protein confirmation assay.

Fig. 12: MULT1E‐RGD protein confirmation. Purified integrin αvβ3 is immobilized on surface
of microtiter plate wells. Serum from culture of stable cell lines is then added to wells and
incubated overnight. Presence of protein is confirmed following ELISA protocol, using 1o
antibody against MULT1 portion of protein, then 2o antibody conjugated to FITC reporter
indicates relative protein concentration by fluorescence value.

Medium from culture of untransfected B16 cells were acted as a negative control, as
well as medium from culture of clones #11 and #16, which showed no transcription
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of the MULT1E‐RGD gene according to RT‐PCR (Fig. 17B). Other controls included
wells exposed to medium – both regular and minimal serum – but no integrin, and
wells coated in integrin, but exposed to no medium. The purpose of these controls
was to rule out non‐specific protein binding to well surfaces, and non‐specific
antibody binding to integrin, respectively, which would give a false‐positive
fluorescent result. Figure 13 represents the assay setup. Each cell represents one
well used of the 96‐well microtiter plate.
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Fig. 13: MULT1E-RGD Protein Confirmation Assay
1

2

3

4

5

6

A

Integrin αvβ3 +
untransfected B16
regular medium (-)

Integrin αvβ3 +
untransfected B16 min.
serum medium (-)

B

Integrin αvβ3 + clone
#11 regular medium ()

Integrin αvβ3 + clone
#11 min. serum
medium (-)

C

Integrin αvβ3 + clone
#16 regular medium ()

Integrin αvβ3 + clone
#16 min. serum
medium (-)

D

Integrin αvβ3 + clone
#3 regular medium
(+)

Integrin αvβ3 + clone
#3 minimal serum
medium (+)

E

Integrin αvβ3 + clone
#8 regular medium
(+)

Integrin αvβ3 + clone
#8 minimal serum
medium (+)

F

Integrin αvβ3 + clone
#26 regular medium
(+)

Integrin αvβ3 + clone
#26 minimal serum
medium (+)

G

Integrin αvβ3 + clone
#28 regular medium
(+)

Integrin αvβ3 + clone
#28 minimal serum
medium (+)

Integrin αvβ3 + NO
medium (-)

untransfected B16
regular medium, NO
integrin

H

7

8

9

untransfected B16
minimal serum
medium, NO
integrin (-)

Fig. 13: MULT1E‐RGD protein confirmation assay. Each experimental and control group was
run in triplicate. Results were taken as average fluorescence of three wells.
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2.5 IN VITRO CELL GROWTH STUDY:
In order to determine the relative rates of cell growth of the various cell lines, an in
vitro cell growth study was performed. Briefly, 10,000 cells of each cell line ‐
untransfected B16 control, #11, #16, #3, #8, #26 and #28 – were seeded on 24‐well
plates. As such, each cell line was represented by 9 wells of a 24 well plate, such that
at 3 different time points, 3 wells could be harvested from each clone and counted to
measure replication. Cell growth was measured at 24 hours, 48 hours, and 72 hours.
Each time point was measured in triplicate. Results represent the average cell
number among the three measured wells of the 24‐well plate at each time point.

2.6 IN VIVO TUMOR PROGRESSION:
Sixteen C57BL mice were injected subcutaneously with B16 melanoma cells. Four
cages, each housing four mice, were designated as untransfected B16 control, Clone
#11 negative control, Clone #8 experimental group and Clone #26 experimental
group. Each mouse was then injected subcutaneously with 200,000 cells of the
appropriate B16 cell line. Tumor growth and progression was then monitored for
the following 4 weeks, taking the first measurement at day 11 and continuing to
monitor tumor size and progression every 2 days. Mice were euthanized when
tumors abscessed and became necrotic, or when tumors exceeded 2cm in diameter
and/or began to impair normal function.
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3.0 Results

3.1 CONSTRUCTION OF RECOMBINANT MULT1E‐RGD VECTOR:
PCR amplification of the MULT1E‐RGD fusion protein gene construct showed
successful amplification of a strand of DNA roughly 750 bp in size, according to gel
eletrophoresis. This length of DNA strand was consistent with the goal gene
construct (Fig. 14).
Subsequent insertion of the MULT1E‐RGD gene into the pcDNA3.1 (+) vector
appeared to have successfully ligated the 750 bp target gene to the 5,427 bp
recombinant vector, according to gel electrophoresis (Fig. 15) results obtained after
miniprep.

 1Kb
 750 bp

Fig. 14: result from PCR amplification of putative MULT1E‐RGD gene. Large, bright band
at about 750 bp, according to 1Kb ladder, indicates amplification of DNA of appropriate
size. 1% agarose gel, supplemented with ethidium bromide.
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3.2 TRANSFORMATION OF COMPETENT CELLS WITH pMULT1E‐RGD:
Following transformation of competent cells with pMULT1E‐RGD, 11 clones were
initially identified by gel electrophoresis as replicating a strand of DNA of
appropriate size (Fig. 15).

 750 bp
 5Kb

Fig. 15: Gel electrophoresis (.7%) from 14 transformed bacterial cell colonies. Bands at
750 base pairs and 5 kilobases represent appropriate lengths for MULT1E‐RGD insert
and pcDNA3.1(+) vector DNA, respectively. Gel shows presence amplified DNA with
lengths 750 bp and 5kb in 12 colonies, indicating probable replication of pMULT1E‐RGD
plasmid DNA. In these colonies. DNA sequence identity was subsequently confirmed in 6
different colonies.

Isolated DNA from 6 of these colonies was sent away for sequencing, which showed
that all but one of the 6 colonies had replicated the target MULT1E‐RGD gene with
100% accuracy. Two of the 6 positive colonies were chosen for further amplification
of the pMULT1E‐RGD plasmid. Both showed a large quantity of DNA present in the
two resultant midipreps, according to ultraviolet absorbance spectrometry (Fig.
16).
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Fig. 16: UV spec for midipreps of 1a & 13c
1a
13c

260.0/280.0
1.865
1.852

Conc. Ug/mL
1627.5
1679.7

conc. Ug/ul
1.63
1.68

Fig. 16: UV absorbance spec used to determine concentration of DNA from midipreps of
clones 1a and 13c, both of which were found to replicate pMULT1E‐RGD with 100%
accuracy.

3.3 TRANSFECTION OF B16 MOUSE MELANOMA CELLS WITH pMULT1E‐RGD:
Reverse transcription polymerase chain reaction, using primers identical to those
used for the initial amplification of the MULT1E‐RGD gene, confirmed the
expression of the MULT1E‐RGD gene at least to the mRNA level (Fig. 17A) in the
transient transfection. Upon establishment of stable cell lines, it was found that 4
cell lines: clones #3, #8, #26 and #28 all constitutively transcribed MULT1E‐RGD
fusion protein gene (Fig. 17B).
A.

 750 bp
750 bp 

B.

Fig. 17: RT‐PCR results from transfection of B16‐F0 mouse melanoma cells with pMULT1E‐
RGD. Presence of MULT1E‐RGD gene represented by bands at 750 bp. β‐actin bands present
in all cells lines, transfected and not transfected. A: results from transient transfection; B16s
are able to incorporate pMULT1E‐RGD into genome and transcribe it. B: RT‐PCR on stable cell
lines following transfection with pMULT1E‐RGD and subsequent selection with G418
antibiotic. Clones #3, #8, #26 and #28 show transcription of gene. Untransfected B16’s,
clones 11, 13 and 16 did not express the gene.
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3.4 MULT1E‐RGD PROTEIN CONFIRMATION:
By way of previously described ELISA techniques (Stilletti et al., 2001), the presence
of MULT1E‐RGD fusion protein was detected in the medium of 4 cell lines: #3, #8,
#26 and #28. In addition, no fusion protein was detected in the medium of cell lines
that did not show mRNA transcription of the MULT1E‐RGD gene, namely clones #11
and #16, and the untransfected B16 cell line. Culture in minimal serum medium
showed no significant difference in protein levels as opposed to regular medium
with normal levels of serum. Figure 18 shows average fluorescence levels of each
cell line’s culture medium, taken from 3 readings. Results indicate that cell lines that
transcribe the fusion protein gene, MULT1E‐RGD, also translate it to protein. In
addition, the MULT1E‐RGD protein is secreted into the extracellular space, or
medium. Finally, the results show that the RGD portion of the protein successfully
binds the integrin αvβ3. This is supported by the fact that fluorescence depends on
binding of the secondary enzyme to the primary enzyme, and primary enzyme must
bind to the MULT1E‐RGD protein, which can only be present if it is bound to
Integrin αvβ3 (Fig. 12).
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Fig. 18: ELISA assay to confirm presence of MULT1E‐RGD fusion protein in medium of clones
transcribing MULT1E‐RGD. Clones #3, #8, #26 and #28, which all showed presence of MULT1E‐
RGD RNA, according to RT‐PCR, also showed translation of protein. Clones that did not show
transcription of gene also show little or no translation of gene.
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3.5 IN VITRO CELL GROWTH:
Prior to the animal study, it was necessary to determine the relative rates of cell
growth of each of the cell lines to be tested in the animal study. Untransfected B16
cells, Clone #11 (negative for MULT1E‐RGD expression), Clone #3, Clone #8, Clone
#26 and Clone #28 were analyzed at 3 different time points for replication: 24
hours, 48 hours, and 72 hours. Results of the in vitro cell growth experiment showed
no significant difference in the rates of cell division of each of the cell lines. Figure
19 shows representative cell growth curves for each of the cell lines. Each data point
is an average of the three wells measured at each time point, due to the protocol
requirements.
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Fig. 19: Results of In vitro cell growth assay. Cell counts at three different time points :24h.,
48h., and 72h., show no significant difference in cell growth among the 6 cell lines. Results
indicate that transfection with pMULT1E‐RGD has no effect on cell proliferation rates.
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3.6 IN VIVO TUMOR PROGRESSION:
From weeks 1 to 2, tumors expressing the MULT1E‐RGD fusion protein seemed to
grow at the same rate, or even faster, than the control tumors expressing no fusion
protein. Interestingly, after 2 weeks the experimental tumors’ growth rates seemed
to slow significantly, whereas the tumors that did not express MULT1E‐RGD
continued to grow rapidly and invade the subcutaneous tissue aggressively. Perhaps
more interesting than the differences in growth rate between control and
experimental tumor cells lines, was the difference in tumor progression. Tumors not
expressing MULT1E‐RGD were extremely aggressive, and began to abscess within
the second week following injection. In addition, control tumors rarely reached a
diameter greater than 1.5 cm without becoming noticeably necrotic. Experimental
tumors, however, reached much larger sizes without abscessing and becoming
necrotic. All mice injected with tumors expressing MULT1E‐RGD fusion protein
were ultimately euthanized due to the size of their tumors. However, only one of the
8 mice showed any signs of abscess in the tumor, and even this abscess was quite
small in relation to the tumor size. Figure 20 gives the day‐by‐day measurements of
the individual tumor growth and progression. Figure 21 shows the 4 growth curves
representing the average size of each tumor cell line at the given time points. Figure
22 shows pictures of the tumors of mice injected with untransfected B16 cells, as
opposed to B16’s that expressed the MULT1E‐RGD fusion protein. Mice with control
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tumors developed aggressive abscesses and had to be eauthanized early, whereas
mice injected with experimental B16 cells which expressed the fusion protein
developed markedly different tumors. Experimental mice lived longer than control
mice, and tumors did not develop aggressive abscesses like their control
counterparts. Results indicate that cells producing the MULT1E‐RGD fusion protein
interact differently with the mouse system than those no expressing the fusion
protein, thereby giving rise to the different tumor morphology.
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Fig. 20: In vivo tumor progression
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Fig. 20: measurement of tumor sizes in mice injected with untransfected B16 cells, clone
#11 cells (not expressing MULT1E‐RGD), and clones #8 and #26 (expressing MULT1E‐
RGD). Notably, mice injected with cells that express MULT1E‐RGD develop large tumors,
but do not develop necrotic abscesses. Mice injected with negative control cells, however,
had to be euthanized early due to necrotic, open tumors.
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Fig. 21: Growth curves for tumors either expressing MULT1E‐RGD fusion protein (#8 & #26) of
not expressing MULT1E‐RGD fusion protein (B16 control & #11). Although growth curve
indicates possibly faster growth of protein‐expressing tumors, the curve is a representation of the
average tumor growth all mice injected with the given cell line. In general, mice injected with
tumors expressing the fusion protein lived longer, and therefore developed larger tumors,
whereas those injected with control tumors were euthanized early, and therefore tumors were
smaller.
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A.

B.

C.

D.

Fig. 22: Phenotypic difference between tumors expressing MULT1E‐RGD fusion
protein, and tumors not expressing the protein. A&B: Tumors of mice not expressing
MULT1E‐RGD. Mouse was euthanized on day 18 due to necrotic hole in tumor. C&D:
tumor on mouse injected with clone #8. Tumor is large, but shows no sign of
opening. Mouse was euthanized on day 24 due to size of tumor and end of study.

49

MUL1E‐RGD Fusion Protein

Meg Steiner

4.0 Discussion

4.1 CONSTRUCTION OF RECOMBINANT MULT1E‐RGD VECTOR:
In order to produce a protein that incorporates both the extracellular domain of
MULT1 that activates the NKG2D receptor, and the RGD peptide sequence that binds
αvβ3 integrin, it was necessary to design a DNA template that could generate such a
sequence when the correct primers were employed. First, mRNA encoding the
extracellular domain of MULT1 was reverse transcribed from mouse thymocytes to
produce cDNA. Next, a DNA sequence was added to the MULT1E gene which would
code for the hinge portion of mouse IgG. The purpose of the hinge domain of the
MULT1E‐RGD protein will be to allow for mobility in the protein such that steric
hindrance does not interfere with RGD binding to integrin αvβ3, or MULT1 binding
to NKG2D (Kotturi, et al., 2008). Finally, the MULT1E‐RGD gene construct was
completed by running a polymerase chain reaction using the MULT1E‐hinge
sequence as the template DNA, along with specially designed primers. These
primers added restriction enzyme digest sites to the ends of the gene construct so as
to allow for easy insertion into a recombinant vector. In addition, the reverse primer
contained the sequence encoding the RGD peptide motif, thereby adding the RGD
portion of the protein onto the 3’ end of the gene construct. The reverse primer also

50

MUL1E‐RGD Fusion Protein

Meg Steiner

coded for a small portion of the hinge domain of the template DNA. This portion of
the primer ensured that the final DNA product would incorporate all of the
necessary components to code for the entire fusion protein.

The MULT1E‐RGD gene construct was then inserted into a recombinant vector so as
to allow for transformation of bacterial cells with the gene‐containing plasmid. The
pcDNA3.1 (+) vector, by Invitrogen, was chosen for several reasons. First of all, the
vetor contains restriction enzyme digest sites for both BamHI and HindIII. Thus, the
PCR product could be easily inserted into the linearized vector and subsequently
ligated. Secondly, the resultant plasmid would contain genes for ampicillin
resistance along with neomycin resistance. These antibiotic resistance genes would
allow for selection of positive clones both following bacterial cell transformation
and ultimately B16 cell transfection, respectively. Finally, the pcDNA3.1 (+) vector
contains a signal sequence, which will tag the protein for secretion immediately
following translation.

4.2 TRANSFORMATION OF COMPETENT CELLS WITH pMULT1E‐RGD:
In order to confirm that the DNA sequence produced by PCR was, in fact, consistent
with the targeted MULT1E‐RGD fusion protein gene, competent cells were
transformed with pMULT1E‐RGD, plasmid DNA was isolated by way of miniprep,
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and DNA was sent off for sequencing. Sequencing confirmed that not only was PCR
amplification of the MULT1E‐RGD gene accurate, but insertion into the pcDNA3.1
(+) recombinant vector was successful, ampicillan‐resistance was retained by the
competent cells, and the plasmid was easily replicated by the cells. Further culture
of positive colonies 1a and 13c allowed for extraction of greater quantities of
plasmid DNA, which could ultimately be used to transfect a murine cancer cell line.

4.3 TRANSFECTION OF B16 MOUSE MELANOMA CELLS WITH pMULT1E‐RGD:
Two wells of a 6‐well plate containing a mouse melanoma cell line were transfected
with pMULT1E‐RGD. The first of the wells served as a transient transfection study,
in which transcription of the fusion protein gene was measured 48 hours after
transfection and in the absence of selective medium. The purpose of this procedure
was to confirm the ability of B16 cells to express the fusion protein gene. In the
absence of selective medium, cells are not pressured to preferentially express
antibiotic resistance genes and therefore are likely to express the fusion protein
gene more readily. After only 48 hours, though, the fusion protein gene has likely
not been stably incorporated into the genomic DNA of most B16 cells. Thus, gene
expression is only transient, and may be lost if no pressure is placed on the cell lines
to continue expressing the gene. This pressure comes from the application of
antibiotic to the medium. mRNA analysis of B16’s from the transient transfection,
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therefore, confirmed the ability of B16’s to express the gene, but it did not establish
stable cell lines.

Accordingly, the second well of the 6‐well‐plate was transfected with the purpose of
establishing stable clones expressing pMULT1E‐RGD. By culturing cells at a very
low concentration in selective medium containing neomycin, it was possible to
isolate specific clones of cells which were resistant to neomycin. Since neomycin
resistance is not native to the B16 cell line, it must be delivered by the recombinant
vector with which cells were transfected. Thus, in some cases, neomycin resistance
should be linked to expression of the fusion protein gene. The establishment of
stable cell lines allows for analysis of cancer cells which have incorporated
pMULT1E‐RGD into their genomes. This is significant, since transfection only
ensures that a cell may use the DNA that is introduced, but does not necessarily
guarantee that DNA is integrated in the genome. Thus, a cell line that incorporates
the gene of interest in its genome and constitutively expresses that gene will
maximize the output of fusion protein. These stable cell lines, all with the same
genotype, can then be analyzed for protein and RNA expression profile. In addition,
stable cell lines are useful in animal studies.

4.4 MULT1E‐RGD PROTEIN CONFIRMATION:
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As previously described (Stilletti et al., 2001), purified integrin αvβ3 can be adsorbed
onto 96‐well microtiter wells by a simple, overnight incubation. Given that the RGD
portion of the MULT1E‐RGD fusion protein aims to bind the developing tumor
vasculature via a high‐affinity interaction with integrin αvβ3 expressed on tumor‐
associated endothelial cells, protein analysis by this particular method serves two
major purposes. First of all, a positive ELISA result – namely an increase in
fluorescence of specific wells of the microtiter plate – indicates the presence of
fusion protein in the medium of the associated cell line. Thus, the four cell lines
which showed transcription of the MULT1E‐RGD fusion protein gene appear to be
translating MULT1E‐RGD to protein, as well. This assay also confirms that the
protein is in fact being secreted by the B16 cells, since only the medium is used for
the assay, and therefore membrane‐bound protein could not elicit a positive result
here. Interestingly, each of the cell lines expresses the protein at relatively equal
levels. In addition to confirming the presence of protein, however, an integrin‐based
ELISA protocol, like the one employed here, carries functional significance. It shows
that not only is the protein of interest present, but the RGD portion of the protein is
functioning as it is intended to function: it effectively binds integrin αvβ3. This result
is paramount to the overall implications of the experiment, since integrin αvβ3 is
selectively expressed during tumor‐associated angiogenesis. Thus, it can be inferred
that RGD is an effective tool for targeting MULT1E to the tumor vasculature.
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4.5 IN VITRO CELL GROWTH:
Because the animal study would be largely focused on how MULT1E‐RGD
expression affects tumor size and progression in injected B16 tumors, it was
necessary to determine if there was a difference in growth rate among the various
cell lines to be tested in the animal study. Because there appears to be no significant
difference in in vitro growth rates among the 4 cell lines, it was assumed that any
difference in tumor progression in vivo was a result of the mouse system response
to the tumor, and not a result of the inherent growth capacities of the various cell
lines.

4.6 IN VIVO TUMOR PROGRESSION:
For the first two weeks following tumor cell injection, the four cell lines appeared to
grow at relatively equal rates, regardless of fusion protein expression. This
coincides with the data gathered in the in vitro cell growth study. After about two
weeks, however, the growth of the experimental tumors seemed to plateau.
Unfortunately, it was impossible to determine the long term growth trend of the
tumors, since mice had to be euthanized once tumor diameter reached 2 cm. This
may indicate that the immune system has waged an attack on the tumor and has
begun to stymie its growth. It may also indicate that the tumor vasculature is
compromised, and therefore the tumor is beginning to reach its maximum volume.
To better determine the pattern of growth in these tumors, a second study should be
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done in which fewer B16 cells are injected initially. Tumor growth should then be
measured over a longer period of time. The reasons for the discrepancies in tumor
growth might be elucidated by histological study of the tumors, as well as cell
staining to define what types of cells inhabit the tumor.

In addition to the difference between growth rates is the striking difference in
phenotype between the tumors expressing MULT1E‐RGD and the tumors not
expressing the protein. Interestingly, control tumors rarely reached the 2cm
humane endpoint because the mice had to be euthanized earlier due to a large, dark
abscess that invariably ruptured from the apex of the tumor. Experimental tumors,
however, were allowed to grow much longer because the tumors did not develop
this abscess. Thus, the tumors grew to a larger size. B16 tumors typically become
obviously necrotic by the time they reach about 1.5 cm in diameter. The point at
which mice must be euthanized is denoted the obvious opening that appears at the
apex of the tumor. This abscess, which is very dark and deep (~2/3 the depth of the
overall tumor) relative to the tumor size, is probably due to the highly aggressive
nature of the B16 cell line. The tumors that showed significant expression of
MULT1E‐RGD fusion protein were visibly different from the control tumors,
however. Fusion protein‐secreting tumors did not develop necrotic abscesses and
almost never opened. Interestingly, these tumors still grew to be quite large, but
they seemed to take on a markedly different phenotype. In some instances, tumors
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could reach 4cm in diameter without erupting, however most were euthanized by
the time tumor diameter reached 2‐3 cm.

This difference in phenotype could be indicative of an anti‐tumoral immune
response. This is evidenced by the slight decrease in growth rate of the tumors in
addition to the change in tumor phenotype. More study should be done on this
particular characteristic of the transfected cell lines. Histological exploration of the
tumors and the surrounding tissue might provide indications of the amount of
inflammation caused by the tumor. Cell staining could indicate the amount of tumor‐
infiltrating lymphocytes, macrophages, and other immune cells are present in and
around the tumor. Finally, TUNEL assays might reveal a difference in the kind of cell
death that is occurring among the different cell lines. By gross examination alone,
there appears to be less necrotic material in the tumors that expressed MULT1E‐
RGD. It might be hypothesized that the fusion protein present in the two positive
cell lines (#8 & #26) is eliciting an immune response, which is causing a higher
infiltration of immune cells (and this could affect the apparent volume of the tumor),
more apoptosis relative to necrosis, and ultimately a slow decline in cell growth
rate. Certainly more in vivo studies should be done concerning the MULT1E‐RGD
fusion protein’s effect on tumor morphology and the anti‐tumoral immune
response.
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5.0 Conclusion

According to the results obtained in this study, it can be concluded that fusion of the
extracellular portion of MULT1 with a short peptide sequence containing RGD
presents a fusion protein with many interesting properties requiring further
investigation. First, the fusion protein appears to successfully home to the tumor
neovasculature by way of the integrin αvβ3. Secondly, the protein has some effect on
tumor cell growth in vivo, which depends on an interaction with the mouse itself,
since there appears to be no difference in growth rates of cells in vitro. Finally,
tumors which express MULT1E‐RGD appear to grow at a different rate and undergo
morphological changes as a result of transfection with the fusion protein. These
changes are only observed in the live mouse model, indicating that phenotypic
changes in the tumor are due to some interaction with the mouse system.
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